APO Research
Talk to an analyst

APO RESEARCH · REPORT

Klebsiella Pneumoniae Infection Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Klebsiella Pneumoniae Infection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025199 pages

Choose your research edition.

Industry ResearchKlebsiella Pneumoniae Infection Drug Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Klebsiella Pneumoniae Infection Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Klebsiella Pneumoniae Infection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Klebsiella Pneumoniae Infection Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Klebsiella Pneumoniae Infection Drug Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Klebsiella Pneumoniae Infection Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Klebsiella Pneumoniae Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Klebsiella Pneumoniae Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Klebsiella Pneumoniae Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Klebsiella Pneumoniae Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Klebsiella Pneumoniae Infection Drug include Acies Bio doo, Appili Therapeutics, Debiopharm International SA, Evaxion Biotech ApS, FOB Synthesis Inc, ImmunoClin Corp, Innovation Pharmaceuticals Inc, Kyorin Pharmaceutical Co Ltd and Melinta Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Klebsiella Pneumoniae Infection Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Klebsiella Pneumoniae Infection Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Klebsiella Pneumoniae Infection Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Klebsiella Pneumoniae Infection Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Klebsiella Pneumoniae Infection Drug Segment by Company

Acies Bio doo

Appili Therapeutics

Debiopharm International SA

Evaxion Biotech ApS

FOB Synthesis Inc

ImmunoClin Corp

Innovation Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Nosopharm SAS

Peptilogics Inc

Phico Therapeutics Ltd

Sarepta Therapeutics Inc

Shionogi & Co Ltd

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Pfizer Inc

F. Hoffmann-La Roche Ltd

Klebsiella Pneumoniae Infection Drug Segment by Type

ATI-1503

CA-824

CC-1807

Cefiderocol

Debio-1454

EBX-004

Others

Klebsiella Pneumoniae Infection Drug Segment by Application

Hospital

Clinic

Others

Klebsiella Pneumoniae Infection Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Klebsiella Pneumoniae Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Klebsiella Pneumoniae Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Klebsiella Pneumoniae Infection Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Klebsiella Pneumoniae Infection Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Klebsiella Pneumoniae Infection Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Klebsiella Pneumoniae Infection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Klebsiella Pneumoniae Infection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Klebsiella Pneumoniae Infection Drug Industry Trends Table 2. Klebsiella Pneumoniae Infection Drug Industry Drivers Table 3. Klebsiella Pneumoniae Infection Drug Industry Opportunities and Challenges Table 4. Klebsiella Pneumoniae Infection Drug Industry Restraints Table 5. Global Klebsiella Pneumoniae Infection Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Klebsiella Pneumoniae Infection Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Manufacturers Table 9. Global Klebsiella Pneumoniae Infection Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Klebsiella Pneumoniae Infection Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Klebsiella Pneumoniae Infection Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Klebsiella Pneumoniae Infection Drug Manufacturers, Product Type & Application Table 13. Global Klebsiella Pneumoniae Infection Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Klebsiella Pneumoniae Infection Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of ATI-1503 Table 17. Major Manufacturers of CA-824 Table 18. Major Manufacturers of CC-1807 Table 19. Major Manufacturers of Cefiderocol Table 20. Major Manufacturers of Debio-1454 Table 21. Major Manufacturers of EBX-004 Table 22. Major Manufacturers of Others Table 23. Global Klebsiella Pneumoniae Infection Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (k units) Table 25. Global Klebsiella Pneumoniae Infection Drug Sales by Type (2027-2032) & (k units) Table 26. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Type (2021-2026) Table 27. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Type (2027-2032) Table 28. Global Klebsiella Pneumoniae Infection Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 29. Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2026) & (k units) Table 30. Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2027-2032) & (k units) Table 31. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2021-2026) Table 32. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of Clinic Table 35. Major Manufacturers of Others Table 36. Global Klebsiella Pneumoniae Infection Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (k units) Table 38. Global Klebsiella Pneumoniae Infection Drug Sales by Application (2027-2032) & (k units) Table 39. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Application (2021-2026) Table 40. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Application (2027-2032) Table 41. Global Klebsiella Pneumoniae Infection Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 42. Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2026) & (k units) Table 43. Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2027-2032) & (k units) Table 44. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2021-2026) Table 45. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2027-2032) Table 46. Global Klebsiella Pneumoniae Infection Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Klebsiella Pneumoniae Infection Drug Sales by Region (2021-2026) & (k units) Table 48. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Region (2021-2026) Table 49. Global Klebsiella Pneumoniae Infection Drug Sales Forecasted by Region (2027-2032) & (k units) Table 50. Global Klebsiella Pneumoniae Infection Drug Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Klebsiella Pneumoniae Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. North America Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 53. North America Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032) & (k units) Table 54. Europe Klebsiella Pneumoniae Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Europe Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 56. Europe Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032) & (k units) Table 57. Asia Pacific Klebsiella Pneumoniae Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Asia Pacific Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 59. Asia Pacific Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032) & (k units) Table 60. South America, Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 61. South America, Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 62. South America, Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032) & (k units) Table 63. Global Klebsiella Pneumoniae Infection Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Klebsiella Pneumoniae Infection Drug Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Klebsiella Pneumoniae Infection Drug Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Region (2021-2026) Table 67. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Region (2027-2032) Table 68. Acies Bio doo Company Information Table 69. Acies Bio doo Business Overview Table 70. Acies Bio doo Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Acies Bio doo Klebsiella Pneumoniae Infection Drug Product Portfolio Table 72. Acies Bio doo Recent Development Table 73. Appili Therapeutics Company Information Table 74. Appili Therapeutics Business Overview Table 75. Appili Therapeutics Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Appili Therapeutics Klebsiella Pneumoniae Infection Drug Product Portfolio Table 77. Appili Therapeutics Recent Development Table 78. Debiopharm International SA Company Information Table 79. Debiopharm International SA Business Overview Table 80. Debiopharm International SA Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Debiopharm International SA Klebsiella Pneumoniae Infection Drug Product Portfolio Table 82. Debiopharm International SA Recent Development Table 83. Evaxion Biotech ApS Company Information Table 84. Evaxion Biotech ApS Business Overview Table 85. Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Product Portfolio Table 87. Evaxion Biotech ApS Recent Development Table 88. FOB Synthesis Inc Company Information Table 89. FOB Synthesis Inc Business Overview Table 90. FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 92. FOB Synthesis Inc Recent Development Table 93. ImmunoClin Corp Company Information Table 94. ImmunoClin Corp Business Overview Table 95. ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Product Portfolio Table 97. ImmunoClin Corp Recent Development Table 98. Innovation Pharmaceuticals Inc Company Information Table 99. Innovation Pharmaceuticals Inc Business Overview Table 100. Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 102. Innovation Pharmaceuticals Inc Recent Development Table 103. Kyorin Pharmaceutical Co Ltd Company Information Table 104. Kyorin Pharmaceutical Co Ltd Business Overview Table 105. Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 107. Kyorin Pharmaceutical Co Ltd Recent Development Table 108. Melinta Therapeutics Inc Company Information Table 109. Melinta Therapeutics Inc Business Overview Table 110. Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 112. Melinta Therapeutics Inc Recent Development Table 113. Nosopharm SAS Company Information Table 114. Nosopharm SAS Business Overview Table 115. Nosopharm SAS Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Nosopharm SAS Klebsiella Pneumoniae Infection Drug Product Portfolio Table 117. Nosopharm SAS Recent Development Table 118. Peptilogics Inc Company Information Table 119. Peptilogics Inc Business Overview Table 120. Peptilogics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Peptilogics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 122. Peptilogics Inc Recent Development Table 123. Phico Therapeutics Ltd Company Information Table 124. Phico Therapeutics Ltd Business Overview Table 125. Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 127. Phico Therapeutics Ltd Recent Development Table 128. Sarepta Therapeutics Inc Company Information Table 129. Sarepta Therapeutics Inc Business Overview Table 130. Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 132. Sarepta Therapeutics Inc Recent Development Table 133. Shionogi & Co Ltd Company Information Table 134. Shionogi & Co Ltd Business Overview Table 135. Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 137. Shionogi & Co Ltd Recent Development Table 138. Syntiron LLC Company Information Table 139. Syntiron LLC Business Overview Table 140. Syntiron LLC Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Syntiron LLC Klebsiella Pneumoniae Infection Drug Product Portfolio Table 142. Syntiron LLC Recent Development Table 143. Tetraphase Pharmaceuticals Inc Company Information Table 144. Tetraphase Pharmaceuticals Inc Business Overview Table 145. Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 147. Tetraphase Pharmaceuticals Inc Recent Development Table 148. Pfizer Inc Company Information Table 149. Pfizer Inc Business Overview Table 150. Pfizer Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Pfizer Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 152. Pfizer Inc Recent Development Table 153. F. Hoffmann-La Roche Ltd Company Information Table 154. F. Hoffmann-La Roche Ltd Business Overview Table 155. F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 157. F. Hoffmann-La Roche Ltd Recent Development Table 158. Key Raw Materials Table 159. Raw Materials Key Suppliers Table 160. Klebsiella Pneumoniae Infection Drug Distributors List Table 161. Klebsiella Pneumoniae Infection Drug Customers List Table 162. Research Programs/Design for This Report Table 163. Authors List of This Report Table 164. Secondary Sources Table 165. Primary Sources List of Figures Figure 1. Klebsiella Pneumoniae Infection Drug Product Image Figure 2. Global Klebsiella Pneumoniae Infection Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Klebsiella Pneumoniae Infection Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Klebsiella Pneumoniae Infection Drug Sales (2021-2032) & (k units) Figure 5. Global Klebsiella Pneumoniae Infection Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Klebsiella Pneumoniae Infection Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. ATI-1503 Image Figure 9. CA-824 Image Figure 10. CC-1807 Image Figure 11. Cefiderocol Image Figure 12. Debio-1454 Image Figure 13. EBX-004 Image Figure 14. Others Image Figure 15. Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Klebsiella Pneumoniae Infection Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Type (2021-2032) Figure 18. Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2021-2032) Figure 21. Hospital Image Figure 22. Clinic Image Figure 23. Others Image Figure 24. Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Klebsiella Pneumoniae Infection Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Application (2021-2032) Figure 27. Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 28. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2021-2032) Figure 30. North America Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 31. North America Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2032) Figure 32. U.S. Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. Canada Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. Mexico Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. Europe Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2032) Figure 37. Germany Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. France Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. U.K. Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Italy Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. Netherlands Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. Asia Pacific Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2032) Figure 44. China Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. Japan Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. South Korea Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. Southeast Asia Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. India Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. Australia Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. South America, Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2032) Figure 52. Brazil Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. South Africa Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Saudi Arabia Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Turkey Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 56. Argentina Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 57. UAE Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 58. Egypt Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 59. Chile Klebsiella Pneumoniae Infection Drug Sales and Growth Rate (2021-2032) & (k units) Figure 60. Global Klebsiella Pneumoniae Infection Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Figure 63. North America Klebsiella Pneumoniae Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Figure 65. Europe Klebsiella Pneumoniae Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Klebsiella Pneumoniae Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Klebsiella Pneumoniae Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Klebsiella Pneumoniae Infection Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Klebsiella Pneumoniae Infection Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • ATI-1503
  • CA-824
  • CC-1807
  • Cefiderocol
  • Debio-1454
  • EBX-004
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Acies Bio doo
  • Appili Therapeutics
  • Debiopharm International SA
  • Evaxion Biotech ApS
  • FOB Synthesis Inc
  • ImmunoClin Corp
  • Innovation Pharmaceuticals Inc
  • Kyorin Pharmaceutical Co Ltd
  • Melinta Therapeutics Inc
  • Nosopharm SAS
  • Peptilogics Inc
  • Phico Therapeutics Ltd
  • Sarepta Therapeutics Inc
  • Shionogi & Co Ltd
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Klebsiella Pneumoniae Infection Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Klebsiella Pneumoniae Infection Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Klebsiella Pneumoniae Infection Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Klebsiella Pneumoniae Infection Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Klebsiella Pneumoniae Infection Drug Market Dynamics
  1. 2.1 Klebsiella Pneumoniae Infection Drug Industry Trends
  2. 2.2 Klebsiella Pneumoniae Infection Drug Industry Drivers
  3. 2.3 Klebsiella Pneumoniae Infection Drug Industry Opportunities and Challenges
  4. 2.4 Klebsiella Pneumoniae Infection Drug Industry Restraints
3 Klebsiella Pneumoniae Infection Drug Market by Manufacturers
  1. 3.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Klebsiella Pneumoniae Infection Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Klebsiella Pneumoniae Infection Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Klebsiella Pneumoniae Infection Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Klebsiella Pneumoniae Infection Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Klebsiella Pneumoniae Infection Drug Manufacturers, Product Type & Application
  7. 3.7 Global Klebsiella Pneumoniae Infection Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Klebsiella Pneumoniae Infection Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Klebsiella Pneumoniae Infection Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Klebsiella Pneumoniae Infection Drug Tier 1, Tier 2, and Tier 3
4 Klebsiella Pneumoniae Infection Drug Market by Type
  1. 4.1 Klebsiella Pneumoniae Infection Drug Type Introduction
  2. 4.1.1 ATI-1503
  3. 4.1.2 CA-824
  4. 4.1.3 CC-1807
  5. 4.1.4 Cefiderocol
  6. 4.1.5 Debio-1454
  7. 4.1.6 EBX-004
  8. 4.1.7 Others
  9. 4.2 Global Klebsiella Pneumoniae Infection Drug Sales by Type
  10. 4.2.1 Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2032)
  12. 4.2.3 Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Type (2021-2032)
  13. 4.3 Global Klebsiella Pneumoniae Infection Drug Revenue by Type
  14. 4.3.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2032)
  16. 4.3.3 Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2021-2032)
5 Klebsiella Pneumoniae Infection Drug Market by Application
  1. 5.1 Klebsiella Pneumoniae Infection Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Klebsiella Pneumoniae Infection Drug Sales by Application
  6. 5.2.1 Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Klebsiella Pneumoniae Infection Drug Revenue by Application
  10. 5.3.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2021-2032)
6 Global Klebsiella Pneumoniae Infection Drug Sales by Region
  1. 6.1 Global Klebsiella Pneumoniae Infection Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Klebsiella Pneumoniae Infection Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Klebsiella Pneumoniae Infection Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Klebsiella Pneumoniae Infection Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Klebsiella Pneumoniae Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Klebsiella Pneumoniae Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Klebsiella Pneumoniae Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Klebsiella Pneumoniae Infection Drug Revenue by Region
  1. 7.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Region
  2. 7.1.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Klebsiella Pneumoniae Infection Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Klebsiella Pneumoniae Infection Drug Revenue (2021-2032)
  8. 7.2.2 North America Klebsiella Pneumoniae Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Klebsiella Pneumoniae Infection Drug Revenue (2021-2032)
  11. 7.3.2 Europe Klebsiella Pneumoniae Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Klebsiella Pneumoniae Infection Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Klebsiella Pneumoniae Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Klebsiella Pneumoniae Infection Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Klebsiella Pneumoniae Infection Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Acies Bio doo
  2. 8.1.1 Acies Bio doo Company Information
  3. 8.1.2 Acies Bio doo Business Overview
  4. 8.1.3 Acies Bio doo Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Acies Bio doo Klebsiella Pneumoniae Infection Drug Product Portfolio
  6. 8.1.5 Acies Bio doo Recent Developments
  7. 8.2 Appili Therapeutics
  8. 8.2.1 Appili Therapeutics Company Information
  9. 8.2.2 Appili Therapeutics Business Overview
  10. 8.2.3 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Product Portfolio
  12. 8.2.5 Appili Therapeutics Recent Developments
  13. 8.3 Debiopharm International SA
  14. 8.3.1 Debiopharm International SA Company Information
  15. 8.3.2 Debiopharm International SA Business Overview
  16. 8.3.3 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Product Portfolio
  18. 8.3.5 Debiopharm International SA Recent Developments
  19. 8.4 Evaxion Biotech ApS
  20. 8.4.1 Evaxion Biotech ApS Company Information
  21. 8.4.2 Evaxion Biotech ApS Business Overview
  22. 8.4.3 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Product Portfolio
  24. 8.4.5 Evaxion Biotech ApS Recent Developments
  25. 8.5 FOB Synthesis Inc
  26. 8.5.1 FOB Synthesis Inc Company Information
  27. 8.5.2 FOB Synthesis Inc Business Overview
  28. 8.5.3 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  30. 8.5.5 FOB Synthesis Inc Recent Developments
  31. 8.6 ImmunoClin Corp
  32. 8.6.1 ImmunoClin Corp Company Information
  33. 8.6.2 ImmunoClin Corp Business Overview
  34. 8.6.3 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Product Portfolio
  36. 8.6.5 ImmunoClin Corp Recent Developments
  37. 8.7 Innovation Pharmaceuticals Inc
  38. 8.7.1 Innovation Pharmaceuticals Inc Company Information
  39. 8.7.2 Innovation Pharmaceuticals Inc Business Overview
  40. 8.7.3 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  42. 8.7.5 Innovation Pharmaceuticals Inc Recent Developments
  43. 8.8 Kyorin Pharmaceutical Co Ltd
  44. 8.8.1 Kyorin Pharmaceutical Co Ltd Company Information
  45. 8.8.2 Kyorin Pharmaceutical Co Ltd Business Overview
  46. 8.8.3 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  48. 8.8.5 Kyorin Pharmaceutical Co Ltd Recent Developments
  49. 8.9 Melinta Therapeutics Inc
  50. 8.9.1 Melinta Therapeutics Inc Company Information
  51. 8.9.2 Melinta Therapeutics Inc Business Overview
  52. 8.9.3 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  54. 8.9.5 Melinta Therapeutics Inc Recent Developments
  55. 8.10 Nosopharm SAS
  56. 8.10.1 Nosopharm SAS Company Information
  57. 8.10.2 Nosopharm SAS Business Overview
  58. 8.10.3 Nosopharm SAS Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Nosopharm SAS Klebsiella Pneumoniae Infection Drug Product Portfolio
  60. 8.10.5 Nosopharm SAS Recent Developments
  61. 8.11 Peptilogics Inc
  62. 8.11.1 Peptilogics Inc Company Information
  63. 8.11.2 Peptilogics Inc Business Overview
  64. 8.11.3 Peptilogics Inc Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Peptilogics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  66. 8.11.5 Peptilogics Inc Recent Developments
  67. 8.12 Phico Therapeutics Ltd
  68. 8.12.1 Phico Therapeutics Ltd Company Information
  69. 8.12.2 Phico Therapeutics Ltd Business Overview
  70. 8.12.3 Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  72. 8.12.5 Phico Therapeutics Ltd Recent Developments
  73. 8.13 Sarepta Therapeutics Inc
  74. 8.13.1 Sarepta Therapeutics Inc Company Information
  75. 8.13.2 Sarepta Therapeutics Inc Business Overview
  76. 8.13.3 Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  78. 8.13.5 Sarepta Therapeutics Inc Recent Developments
  79. 8.14 Shionogi & Co Ltd
  80. 8.14.1 Shionogi & Co Ltd Company Information
  81. 8.14.2 Shionogi & Co Ltd Business Overview
  82. 8.14.3 Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  84. 8.14.5 Shionogi & Co Ltd Recent Developments
  85. 8.15 Syntiron LLC
  86. 8.15.1 Syntiron LLC Company Information
  87. 8.15.2 Syntiron LLC Business Overview
  88. 8.15.3 Syntiron LLC Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Syntiron LLC Klebsiella Pneumoniae Infection Drug Product Portfolio
  90. 8.15.5 Syntiron LLC Recent Developments
  91. 8.16 Tetraphase Pharmaceuticals Inc
  92. 8.16.1 Tetraphase Pharmaceuticals Inc Company Information
  93. 8.16.2 Tetraphase Pharmaceuticals Inc Business Overview
  94. 8.16.3 Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  96. 8.16.5 Tetraphase Pharmaceuticals Inc Recent Developments
  97. 8.17 Pfizer Inc
  98. 8.17.1 Pfizer Inc Company Information
  99. 8.17.2 Pfizer Inc Business Overview
  100. 8.17.3 Pfizer Inc Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Pfizer Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  102. 8.17.5 Pfizer Inc Recent Developments
  103. 8.18 F. Hoffmann-La Roche Ltd
  104. 8.18.1 F. Hoffmann-La Roche Ltd Company Information
  105. 8.18.2 F. Hoffmann-La Roche Ltd Business Overview
  106. 8.18.3 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  108. 8.18.5 F. Hoffmann-La Roche Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Klebsiella Pneumoniae Infection Drug Value Chain Analysis
  2. 9.1.1 Klebsiella Pneumoniae Infection Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Klebsiella Pneumoniae Infection Drug Production Mode & Process
  6. 9.2 Klebsiella Pneumoniae Infection Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Klebsiella Pneumoniae Infection Drug Distributors
  9. 9.2.3 Klebsiella Pneumoniae Infection Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst